Clinical Trial Update: Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating hyperpolarized 13C pyruvate MRI as a biomarker to predict aggressiveness of renal tumors. The study is active but not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Kidney Neoplasm
• Kidney Neoplasm
• Renal Cell Carcinoma

Drugs mentioned

• Hyperpolarized [1-13C]pyruvate (pyruvate (hyperpolarized with carbon-13))

Snippet

Sponsor: Zhen Wang, MD | Conditions: Benign Kidney Neoplasm, Kidney Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING